Profile data is unavailable for this security.
About the company
Fusion Pharmaceuticals Inc. is a clinical-stage oncology company. The Company is focused on developing radiopharmaceuticals as precision medicines. It has developed its Targeted Alpha Therapies (TAT), platform to enable it to connect alpha particle emitting isotopes to various targeting molecules to selectively deliver the alpha particle payloads to tumors. The TAT platform is underpinned by its ability to radiolabel various classes of targeting molecules, its research and insights into the underlying chemistry and biology of alpha emitting radiopharmaceuticals, its differentiated capabilities in target identification, candidate generation, manufacturing and supply chain, its Fast-Clear linker technology used in conjunction with antibody-based targeting molecules, and development of imaging agents. Its clinical portfolio includes FPI-2265, FPI-1434 and FPI-2059. FPI-2265 targeting prostate specific membrane antigen for metastatic castration resistant prostate cancer in a Phase 2 trial.
- Revenue in USD (TTM)2.04m
- Net income in USD-104.28m
- Incorporated2014
- Employees113.00
- LocationFusion Pharmaceuticals Inc270 Longwood Rd. SHAMILTON L8P 0A6CanadaCAN
- Phone+1 (289) 799-0891
- Websitehttps://fusionpharma.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Structure Therapeutics Inc (ADR) | 0.00 | -97.68m | 1.70bn | 111.00 | -- | 3.95 | -- | -- | -2.32 | -2.32 | 0.00 | 9.22 | 0.00 | -- | -- | 0.00 | -27.73 | -- | -29.16 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -69.62 | -- | -- | -- |
Edgewise Therapeutics Inc | 0.00 | -105.85m | 1.70bn | 92.00 | -- | 3.17 | -- | -- | -1.53 | -1.53 | 0.00 | 5.73 | 0.00 | -- | -- | 0.00 | -23.52 | -- | -24.25 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -48.08 | -- | -- | -- |
Harmony Biosciences Holdings Inc | 617.51m | 137.70m | 1.71bn | 246.00 | 13.03 | 3.33 | 10.58 | 2.78 | 2.32 | 2.32 | 10.39 | 9.08 | 0.7906 | 25.72 | 9.34 | 2,510,207.00 | 17.63 | 7.46 | 20.83 | 9.08 | 79.28 | 80.58 | 22.30 | 10.46 | 3.07 | 31.38 | 0.2694 | 0.00 | 32.93 | -- | -28.99 | -- | -25.31 | -- |
Kura Oncology Inc | 0.00 | -168.09m | 1.72bn | 142.00 | -- | 3.40 | -- | -- | -2.18 | -2.18 | 0.00 | 6.63 | 0.00 | -- | -- | 0.00 | -34.31 | -26.04 | -36.21 | -27.45 | -- | -- | -- | -- | -- | -- | 0.0182 | -- | -- | -- | -12.36 | -- | -- | -- |
Syndax Pharmaceuticals Inc | 0.00 | -240.63m | 1.76bn | 112.00 | -- | 3.59 | -- | -- | -3.22 | -3.22 | 0.00 | 5.79 | 0.00 | -- | -- | 0.00 | -47.99 | -27.90 | -51.84 | -30.15 | -- | -- | -- | -324.34 | -- | -- | 0.00004 | -- | -- | -- | -40.19 | -- | -- | -- |
Inhibrx Inc | 1.78m | -271.16m | 1.80bn | 166.00 | -- | 146.45 | -- | 1,011.30 | -5.35 | -5.35 | 0.0358 | 0.235 | 0.0066 | -- | 7.51 | 10,740.96 | -99.40 | -77.06 | -123.13 | -93.91 | -- | -- | -15,116.15 | -1,590.91 | -- | -12.67 | 0.9474 | -- | -17.88 | -26.85 | -66.20 | -- | 26.30 | -- |
Sana Biotechnology Inc | 0.00 | -308.61m | 1.83bn | 328.00 | -- | 4.87 | -- | -- | -1.53 | -1.53 | 0.00 | 1.70 | 0.00 | -- | -- | 0.00 | -43.21 | -38.99 | -48.50 | -42.70 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -5.11 | -- | 112.71 | -- |
Ardelyx Inc | 159.11m | -65.81m | 1.83bn | 267.00 | -- | 12.13 | -- | 11.50 | -0.2883 | -0.2883 | 0.7007 | 0.6449 | 0.5689 | 3.20 | 7.90 | 595,917.60 | -23.53 | -46.14 | -29.95 | -57.32 | 85.30 | 88.15 | -41.36 | -240.87 | 4.36 | -9.86 | 0.3982 | -- | 138.61 | 116.66 | 1.70 | -- | 2.04 | -- |
Fusion Pharmaceuticals Inc | 2.04m | -104.28m | 1.83bn | 113.00 | -- | 7.55 | -- | 897.30 | -1.42 | -1.42 | 0.0279 | 2.85 | 0.0069 | -- | 45.84 | 18,053.10 | -35.33 | -35.45 | -37.76 | -38.55 | -- | -- | -5,111.57 | -7,206.24 | -- | -- | 0.1704 | -- | 41.55 | -- | -8.32 | -- | 28.21 | -- |
Keros Therapeutics Inc | 234.00k | -160.30m | 1.84bn | 141.00 | -- | 4.06 | -- | 7,881.40 | -5.14 | -5.14 | 0.0075 | 12.59 | 0.0005 | -- | -- | 1,720.59 | -36.84 | -35.95 | -38.35 | -38.07 | -- | -- | -68,505.13 | -1,237.26 | -- | -- | 0.00 | -- | -- | -56.77 | -46.15 | -- | 62.57 | -- |
Protagonist Therapeutics Inc | 314.95m | 162.11m | 1.86bn | 124.00 | 12.90 | 3.32 | 11.40 | 5.91 | 2.46 | 2.46 | 5.25 | 9.56 | 0.7248 | -- | 2.10 | 2,812,080.00 | 37.30 | -35.90 | 40.23 | -41.36 | -- | -- | 51.47 | -332.81 | -- | -- | 0.00 | -- | 125.73 | 14.17 | 38.02 | -- | 4.62 | -- |
Agios Pharmaceuticals Inc | 29.40m | -352.62m | 1.90bn | 383.00 | -- | 2.55 | -- | 64.57 | -6.31 | -6.31 | 0.5257 | 13.11 | 0.0294 | 0.1715 | 11.24 | 76,770.23 | -35.24 | -29.54 | -37.04 | -31.88 | 89.95 | -- | -1,199.26 | -3,826.10 | 12.39 | -- | 0.00 | -- | 88.36 | -22.25 | -51.89 | -- | -32.23 | -- |
Catalyst Pharmaceuticals Inc | 411.35m | 65.12m | 1.91bn | 167.00 | 29.98 | 3.39 | 18.91 | 4.63 | 0.5384 | 0.5384 | 3.60 | 4.76 | 0.7806 | 3.60 | 8.76 | 2,463,156.00 | 12.36 | 25.42 | 14.19 | 29.81 | 86.74 | 85.63 | 15.83 | 30.87 | 4.83 | -- | 0.00 | 0.00 | 85.90 | 280.39 | -14.05 | -- | 20.21 | -- |
Holder | Shares | % Held |
---|---|---|
Federated Global Investment Management Corp.as of 31 Mar 2024 | 10.81m | 12.74% |
Perceptive Advisors LLCas of 31 Mar 2024 | 6.83m | 8.04% |
Avidity Partners Management LPas of 31 Mar 2024 | 6.50m | 7.66% |
Fidelity Investments Canada ULCas of 31 Mar 2024 | 4.19m | 4.93% |
Pentwater Capital Management LPas of 31 Mar 2024 | 3.78m | 4.46% |
Canada Pension Plan Investment Boardas of 31 Mar 2024 | 3.12m | 3.67% |
Fidelity Management & Research Co. LLCas of 31 Mar 2024 | 1.84m | 2.16% |
Millennium Management LLCas of 31 Mar 2024 | 1.61m | 1.90% |
Marshall Wace LLPas of 31 Mar 2024 | 1.50m | 1.77% |
TIG Advisors LLCas of 31 Mar 2024 | 1.00m | 1.18% |